Any current/future new fundraising through debt or equity?

The company currently has a cash balance of about INR 93 crores with strong cash to EBITDA conversion (~100%) over the last five years. There is no explicit mention of any ongoing or planned fundraising through debt or equity in the provided text. The focus is on using internal cash generation for inorganic growth (acquisitions) rather than external financing. The company is selective and strategic about acquisitions, prioritizing brand acquisitions within existing therapies or new therapy businesses. If suitable acquisitions are not available at the right price, the company prefers to hold ca

Any current/future capex/capital investment/strategic investment?

The company follows an asset-light model with complete outsourcing of manufacturing; hence, it does not require significant capital investments for manufacturing facilities. Manish Gupta mentioned that the business model results in nearly 100% cash-to-EBITDA conversion over the last five years, indicating limited capital reinvestment needs. Current and future cash generated will primarily be used for inorganic growth strategies, i.e., acquisitions. Inorganic strategy focuses on brand acquisition within existing therapies or business acquisitions to enter new therapy areas, particularly sub-chr

Future growth expectations in sales/revenue/volumes?

The company targets an organic top-line growth of 12% to 14% over the medium term, primarily driven by: - Volume increase (though industry-wide volume growth is currently subdued) - Price increases - New product introductions, particularly in core therapeutic areas like gynaecology The growth will be a balanced contribution (~3-5% each) from these levers Strategic focus remains on launching 2-3 new products annually across four divisions, with a bias towards gynaecology Improved field force productivity aimed to increase sales per medical representative from ₹2.8 lakhs currently to ₹4-4.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects organic top-line growth of 12% to 14% over the medium term, driven equally by volume increase, price increase, and new product introductions. EBITDA margins are projected to expand by 100 to 150 basis points year on year over the next 3 to 4 years, aiming to reach around 30% margins in 3 years. Q2 FY25 operating EBITDA grew 46.6% y-o-y to ₹18.4 crores; net profit grew 53% to ₹11.4 crores. Full year FY25 EBITDA margin guidance is 22%+ with further margin expansion expected, supported by fixed nature of field force costs and better utilization. Earnings growth is expected fro

Jagsonpal Pharmaceuticals LtdQ2 FY25Pharmaceuticals & Biotechnology

Jagsonpal Pharmaceuticals Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹221.94P/E: 31.1Market Cap: ₹1.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company targets an organic top-line growth of 12% to 14% over the medium term, primarily driven by:
- Volume increase (though industry-wide volume growth is currently subdued)
- Price increases
- New product introductions, particularly in core therapeutic areas like gynaecology
The growth will be a balanced contribution (~3-5% each) from these levers
Strategic focus remains on launching 2-3 new products annually across four divisions, with a bias towards gynaecology
Improved field force productivity aimed to increase sales per medical representative from ₹2.8 lakhs currently to ₹4-4.5 lakhs per month within three years
Inorganic growth via selective acquisitions of brands or businesses in existing or new therapy areas may supplement organic expansion
Long-term expectation includes margin expansion and improving operational efficiencies, supporting sustained revenue growth

Margin guidance

Category 1

The company expects organic top-line growth of 12% to 14% over the medium term, driven equally by volume increase, price increase, and new product introductions.
EBITDA margins are projected to expand by 100 to 150 basis points year on year over the next 3 to 4 years, aiming to reach around 30% margins in 3 years.
Q2 FY25 operating EBITDA grew 46.6% y-o-y to ₹18.4 crores; net profit grew 53% to ₹11.4 crores.
Full year FY25 EBITDA margin guidance is 22%+ with further margin expansion expected, supported by fixed nature of field force costs and better utilization.
Earnings growth is expected from improved field force productivity and launches in key therapies, especially gynecology.
Inorganic growth through acquisitions will be an additional growth lever but is opportunistic and not on a fixed timeline.
Overall, the company targets sustained earnings growth and EBITDA margin expansion through operational efficiency.

See what Jagsonpal Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently has a cash balance of about INR 93 crores with strong cash to EBITDA conversion (~100%) over the last five years.
There is no explicit mention of any ongoing or planned fundraising through debt or equity in the provided text.
The focus is on using internal cash generation for inorganic growth (acquisitions) rather than external financing.
The company is selective and strategic about acquisitions, prioritizing brand acquisitions within existing therapies or new therapy businesses.
If suitable acquisitions are not available at the right price, the company prefers to hold cash or return it to shareholders rather than raising new funds.
Overall, no immediate plans or priorities for raising debt or equity are indicated in the current discussion.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for Jagsonpal Pharmaceuticals Limited. However, relevant insights related to business performance and growth outlook include: - The company recorded revenue of ₹74.7 crores in Q2FY25, with a healthy growth trajectory. - Organic growth guidance is 12%-14% over the medium term, driven by volume increase, price increase, and new product launches. - Growth momentum is improving post resolution of spurious product issues and hyper-competition in key molecules. - The company continues to focus on core branded generic segments like gynaecology, orthopaedics, derma, and pediatrics. - Acquisitions are opportunistic, with no fixed roadmap for regular buys; strategic brand acquisitions prioritized over business or new therapy acquisition. - Field force productivity and doctor coverage improvements are key drivers for future growth. No specific numbers or details on order book or pending order pipeline are disclosed in the provided pages.

See what Jagsonpal Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company follows an asset-light model with complete outsourcing of manufacturing; hence, it does not require significant capital investments for manufacturing facilities.
Manish Gupta mentioned that the business model results in nearly 100% cash-to-EBITDA conversion over the last five years, indicating limited capital reinvestment needs.
Current and future cash generated will primarily be used for inorganic growth strategies, i.e., acquisitions.
Inorganic strategy focuses on brand acquisition within existing therapies or business acquisitions to enter new therapy areas, particularly sub-chronic segments.
There is no fixed roadmap or target for acquisitions (e.g., one every year), but they assess strategic opportunities as they arise.
If acquisitions fit the strategy and price, they will pursue them; otherwise, the company is comfortable sitting on cash or returning it to shareholders.
No specific mention of any large ongoing or planned capital expenditure for capacity expansion or new manufacturing facilities.

Track Jagsonpal Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does Jagsonpal Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisJagsonpal Pharmaceuticals Ltd

Rev 3Mar 1

See where Jagsonpal Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Jagsonpal Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Jagsonpal Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →